RayzeBio, Inc. Common Stock (RYZB) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
RayzeBio, Inc. Common Stock
Address
, DE
United States of America (the)
Phone
N/A
Website
N/A
Sector
Healthcare
Industry
Biotechnology
Employees
88
First IPO Date
September 15, 2023
Key Executives
| Name | Title | Pay | Year Born |
| Kenneth Song | President, Chief Executive Officer & Director | 646,000 | 1975 |
| Susan Moran | Chief Medical Officer | 559,840 | 1969 |
| Arvind Kush | Chief Financial Officer | 714,757 | 1983 |
| Nicholas D. Smith | Senior Vice President of Chemistry Innovation | 0 | N/A |
| Gary G. Li | Senior Vice President of Biology & Translational Medicine | 0 | N/A |
| Eric Bischoff | Senior Vice President of Development & Operations | 0 | N/A |
| Abhi Bhat | Senior Vice President of Chemistry & Head of Discovery | 0 | N/A |
| Aron Marc Knickerbocker | Co-Founder | 0 | 1969 |
| Kimberly Ma | Senior Vice President of Clinical Operations | 0 | N/A |
| Jeff Woodley | General Counsel | 0 | N/A |
Description
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
